by Chris Dokomajilar | Aug 30, 2023 | Analysis, Funding
Biopharma IPO activity was still quiet through the second quarter 2023 with 3 companies going public on global exchanges for a total of $800 million. This follows 3 IPOs in the first quarter at $400 million. Among these IPOs, Laekna raised approximately $101 million...
by Chris Dokomajilar | Aug 21, 2023 | Analysis, Funding
The biopharmaceutical industry experienced a return of venture funding activity in the second quarter of 2023, driving therapeutic development and platform technology advancements. ElevateBio secured a noteworthy $401 million Series D financing to further develop...
by Chris Dokomajilar | Aug 1, 2023 | Analysis, Funding, M&A, Partnership Deals
The biopharmaceutical industry outlook for the new quarter remains dynamic and promising, characterized by significant deals in the first half. Galderma’s private placement of $1 billion aims to strengthen its dermatology position and leverage its integrated...
by Chris Dokomajilar | May 23, 2023 | Analysis, Funding
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...
by Chris Dokomajilar | May 3, 2023 | Analysis, Funding
The slowdown in interest rate hikes may increase small biotech companies’ initial public offerings (IPOs) later in 2023. Investors will be more cautious and favor firms with drugs in human trials. The biotech industry experienced a decline in IPOs globally in...
by Chris Dokomajilar | May 3, 2023 | Analysis, Funding
Biopharma IPOs as Investors Bet On Life-Saving Breakthroughs Only $400 million in 3 newly filed IPOs were raised in Q1 2023 – 1 fewer IPO filing compared to Q4 2022 but with a slightly higher value vs. $300 million raised in Q4 2022. Q2 of 2021 saw the most...